AbbVie Investing Activities - Other 2010-2024 | ABBV
AbbVie annual/quarterly investing activities - other history and growth rate from 2010 to 2024. Investing activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the investing activities section of the Cash Flows Statement
- AbbVie investing activities - other for the quarter ending December 31, 2024 was $189M, a 1353.85% increase year-over-year.
- AbbVie investing activities - other for the twelve months ending December 31, 2024 was $164M, a 65.66% increase year-over-year.
- AbbVie annual investing activities - other for 2024 was $0.189B, a 1353.85% increase from 2023.
- AbbVie annual investing activities - other for 2023 was $0.013B, a 98.32% decline from 2022.
- AbbVie annual investing activities - other for 2022 was $0.774B, a 111.48% increase from 2021.
AbbVie Annual Investing Activities - Other
(Millions of US $) |
| 2024 |
$189 |
| 2023 |
$13 |
| 2022 |
$774 |
| 2021 |
$366 |
| 2020 |
$1,387 |
| 2019 |
$167 |
| 2018 |
$N/A |
| 2017 |
$N/A |
| 2016 |
$118 |
| 2015 |
$N/A |
| 2014 |
$N/A |
| 2013 |
$N/A |
| 2012 |
$N/A |
| 2011 |
$1,870 |
| 2010 |
$-1,870 |
| 2009 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$306.016B |
$56.334B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
